Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | IMP (inosine 5'-monophosphate) dehydrogenase 1 | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.15 uM | In vitro inhibition of human lymphocyte proliferation in response to staphylococcus protein A(SPA) was determined | ChEMBL. | 1967654 |
IC50 (functional) | = 0.35 uM | In vitro inhibition of human lymphocyte proliferation in response to phytohaemagglutinin (PHA) was determined | ChEMBL. | 1967654 |
IC50 (functional) | = 0.35 uM | In vitro inhibition of human lymphocyte proliferation in response to pokeweed mitogen(PWM) was determined | ChEMBL. | 1967654 |
IC50 (binding) | = 1.2 uM | In vitro inhibition of inosine Inosine-5'-monophosphate dehydrogenase | ChEMBL. | 1967654 |
IC50 (binding) | = 1.2 uM | In vitro inhibition of inosine Inosine-5'-monophosphate dehydrogenase | ChEMBL. | 1967654 |
Inhibition (functional) | = -33 % | The compound was tested in vivo for inhibition of plaque-forming cells in the spleen(PFC/spleen) after 50 mg/kg oral administration in mice | ChEMBL. | 1967654 |
Inhibition (functional) | = -33 % | The compound was tested in vivo for inhibition of plaque-forming cells in the spleen(PFC/spleen) after 50 mg/kg oral administration in mice | ChEMBL. | 1967654 |
Inhibition (functional) | = -20 % | The compound was tested in vivo for inhibition of plaques per million after 50 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = -20 % | The compound was tested in vivo for inhibition of plaques per million after 50 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 15 % | In vivo inhibition of plaque-forming cells in the spleen(PFC/spleen) after 40 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 15 % | In vivo inhibition of plaque-forming cells in the spleen(PFC/spleen) after 40 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 16 % | The compound was tested in vivo for inhibition of plaques per million after 25 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 16 % | The compound was tested in vivo for inhibition of plaques per million after 25 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 18 % | In vivo inhibition of plaque-forming cells in the spleen(PFC/spleen) after 25 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 18 % | In vivo inhibition of plaque-forming cells in the spleen(PFC/spleen) after 25 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 22 % | The compound was tested in vivo for inhibition of plaques per million after 40 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 22 % | The compound was tested in vivo for inhibition of plaques per million after 40 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 79 % | The compound was tested in vivo for inhibition of plaques per million after 100 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 79 % | The compound was tested in vivo for inhibition of plaques per million after 100 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 80 % | In vivo inhibition of plaque-forming cells in the spleen(PFC/spleen) after 100 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Inhibition (functional) | = 80 % | In vivo inhibition of plaque-forming cells in the spleen(PFC/spleen) after 100 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
PFC/spleen (functional) | = 17000 | In vivoantibody response to sheep red blood cells(SRBC) by plaque-forming cells in the spleen(PFC/spleen) after 100 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
PFC/spleen (functional) | = 96583 | In vivo antibody response to sheep red blood cells by plaque-forming cells in the spleen(PFC/spleen) after 25 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
PFC/spleen (functional) | = 99333 | In vivo antibody response to sheep red blood cells(SRBC) by plaque-forming cells in the spleen(PFC/spleen) after 40 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
PFC/spleen (functional) | = 112416 | In vivo antibody response to sheep red blood cells(SRBC) by plaque-forming cells in the spleen(PFC/spleen) after 50 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
PPM (functional) | = 114 | In vivo total no of plaques in spleen was determined after 100 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
PPM (functional) | = 583 | In vivo total no of plaques in spleen was determined after 25 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
PPM (functional) | = 630 | In vivo total no of plaques in spleen was determined after 25 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
PPM (functional) | = 657 | In vivo total no of plaques in spleen was determined after 50 mg/kg oral administration in mice. | ChEMBL. | 1967654 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.